Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to McDermott, David
Item TypeName
Academic Article Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
Academic Article Immunotherapy of metastatic renal cell carcinoma.
Academic Article Immunotherapy for metastatic renal cell carcinoma.
Academic Article Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy.
Academic Article Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
Academic Article Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
Academic Article Immunotherapy for renal cell carcinoma.
Academic Article What is standard initial systemic therapy in metastatic renal cell carcinoma?
Concept Immunotherapy, Adoptive
Concept Immunotherapy
Academic Article Immunotherapy and targeted therapy combinations in renal cancer.
Academic Article Immunotherapy of metastatic renal cell carcinoma.
Academic Article Novel immunotherapies in GU malignancies.
Academic Article The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
Academic Article Immune therapy for kidney cancer: a second dawn?
Academic Article PD-1 as a potential target in cancer therapy.
Academic Article Potential of new therapies like anti-PD1 in kidney cancer.
Academic Article Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
Academic Article Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.
Academic Article Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.
Academic Article Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Academic Article Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.
Academic Article The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Academic Article Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside.
Academic Article Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.
Academic Article Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.
Academic Article Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era.
Academic Article Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.
Academic Article Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based Therapies.
Academic Article Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer.
Academic Article An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.
Academic Article Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma.
Academic Article Sequential treatment approaches in  the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.
Academic Article Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma.
Academic Article Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
Academic Article Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
Academic Article To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease.
Academic Article Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma.
Academic Article The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).
Academic Article Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma.
Academic Article Checkpoint inhibitor immunotherapy in kidney cancer.
Academic Article Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma.
Search Criteria
  • Immunotherapy
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.